Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus NAPHCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus NAPHCON A.
DRIXORAL vs NAPHCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Naphcon-A combines naphazoline, an alpha-adrenergic receptor agonist, and pheniramine, a histamine H1-receptor antagonist. Naphazoline constricts conjunctival blood vessels via alpha-adrenergic stimulation, reducing redness and edema. Pheniramine blocks histamine effects, alleviating itching and allergic reactions.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
1-2 drops instilled into the conjunctival sac every 3-4 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Naphazoline: ~2-3 hours; antazoline: ~3-4 hours. Clinical context: ocular administration, systemic absorption minimal.
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Primarily renal excretion of unchanged drug and metabolites; naphazoline <10% unchanged, antazoline ~30% unchanged. Biliary/fecal elimination negligible.
Category C
Category C
Antihistamine/Decongestant
Ophthalmic Antihistamine/Decongestant